Clue study: 48% of women say menstrual symptom concerns were dismissed

Nearly half of women who sought medical help for menstrual symptoms say their concerns were not taken seriously, according to a study released by the period-tracking app Clue on Wednesday, 4 November 2026. The study, a global survey of 11,910 Clue users in 132 countries, has been published in the peer-reviewed journal npj Women's Health. Among users who had seen a healthcare provider about their symptoms, 34% said they were told the symptoms were normal or not a problem, while 29% said they received a diagnosis or treatment.

The study asked a simple question with a practical edge: when people take period symptoms to a clinician, what happens next? The new figures put a number on how often that happens inside the doctor's room: in this sample, a woman who went to a clinician about her period was more likely to be told it was normal than to leave with a diagnosis or a treatment plan.

That gap matters for life balance. A symptom that is waved away is a symptom that keeps returning every month, along with the time off, the painkillers and the stress that come with it. It can also delay the diagnosis of conditions that need treatment, which is why the study looked at what happened after people asked for help, not only at how they felt.

Clue's chief executive, Rhiannon White, said in the company's statement: "Just because menstrual symptoms are common doesn't mean people should have to put up with them." The company also says the findings show how users turn to tracking apps to understand and manage their symptoms.

The study has limits that readers should keep in mind. It is a survey of people who already use a period-tracking app, not a random sample of all women, and the answers are self-reported. The company that makes the app funded the work and employs or contracts members of the research team; the paper states that, beyond this, the company had no further role in the design, data collection, analysis or writing. The responses were collected in May 2024, so they describe experiences up to that point.

Peepals calculation: The paper gives both the percentages and the head-counts for people who saw a provider, so the size of that group can be worked out. 1,391 people are 34% of it (1,391 / 0.34 ≈ 4,090) and 1,193 people are 29% of it (1,193 / 0.29 ≈ 4,110), so roughly 4,100 respondents had consulted a provider, about one in three of the 11,910 surveyed (4,100 / 11,910 ≈ 34%). Within that group, 198 more people were told their symptoms were normal than received a diagnosis or treatment (1,391 - 1,193). The two percentages may use slightly different bases, so these are approximate. Our calculation from the reported figures.

There is also a point about geography. Respondents in North America and Europe made up 81% of the sample (44% + 37%), leaving about 19% from the rest of the world. That means the results speak mostly for women in those regions, and the experience of women in India and other parts of Asia is only a small part of the data.

Short-term: The figures add to the discussion among doctors and women's health groups about how menstrual complaints are handled in routine consultations.

Long-term: Published, peer-reviewed data from a large sample gives researchers and health services a benchmark to compare against when they study how women's symptoms are assessed.

Who is affected: Women and girls who live with painful or disruptive periods, the doctors and nurses who see them, and the makers of health-tracking apps whose users increasingly bring their own records to appointments.

Questions and Answers